Abstract
Objective Recent mutations in SARS-CoV-2 raised concerns about diminishing vaccine effectiveness against COVID-19 caused by particular variants. Even with a high initial efficacy, if a vaccine’s efficacy drops significantly against variants, or if it cannot be distributed quickly, it is uncertain whether the vaccine can provide better health outcomes than other vaccines. Hence, we evaluated the trade-offs between speed of distribution vs. efficacy of multiple vaccines when variants emerge.
Methods We utilized a Susceptible-Infected-Recovered-Deceased (SIR-D) model to simulate the impact of immunization using different vaccines with varying efficacies and assessed the level of infection attack rate (IAR) under different speeds of vaccine distribution.
Results We found that a vaccine with low efficacy both before and after variants may outperform a vaccine with high efficacy if the former can be distributed more quickly. Particularly, a vaccine with 65% and 60% efficacy before and after the variants, respectively, can outperform a vaccine with 95% and 90% efficacy, if its distribution is 46% to 48% faster (with the selected study parameters).
Conclusions Our results show that speed is a key factor to a successful immunization strategy to control the COVID-19 pandemic even when the emerging variants may reduce the efficacy of a vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been supported in part by the following Georgia Tech benefactors: William W. George, Andrea Laliberte, Claudia L. and J. Paul Raines, and Richard E. Rick and Charlene Zalesky. Dr. Inci Yildirim reported being a member of the mRNA-1273 Study Group. Dr. Yildirim has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron. Dr. Pinar Keskinocak received funding to her institution from Merck to conduct non-clinical research. The funders played no role in the study design, data collection, analysis, interpretation, or in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The manuscript uses public available information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data is used or referred to in the manuscript.
